2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04302870 (ClinicalTrials.gov) | February 27, 2020 | 4/3/2020 | Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial | Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial | Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Drug: Memantine Hydrochloride Oral Solution;Drug: Trazodone Hydrochloride oral solution;Drug: Placebo oral solution | University of Edinburgh | University College, London;University of Warwick;NHS Lothian | Recruiting | 18 Years | N/A | All | 750 | Phase 2/Phase 3 | United Kingdom |